Alumis Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALMS Nasdaq 2836 www.alumis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alumis Inc.

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements - May 29th, 2026 4:31 am
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter - May 24th, 2026 8:33 am
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? - May 19th, 2026 10:34 pm
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - May 19th, 2026 11:37 am
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - May 19th, 2026 11:26 am
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish - May 18th, 2026 11:33 am
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - May 17th, 2026 12:33 pm
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - May 15th, 2026 4:56 pm
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Oil Surge, Higher Yields, Geopolitical Uncertainty - May 15th, 2026 7:14 am
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers - May 15th, 2026 5:36 am
A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss - May 14th, 2026 9:17 pm
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements - May 14th, 2026 2:05 pm
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2026 6:10 am
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug - May 10th, 2026 3:53 am
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 5:05 pm
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Apr 6th, 2026 3:09 pm
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Apr 4th, 2026 11:07 am
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Apr 3rd, 2026 9:12 pm
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says - Mar 30th, 2026 9:25 am
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout - Mar 29th, 2026 7:02 pm